202 related articles for article (PubMed ID: 8314011)
1. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.
Howey DC; Bowsher RR; Brunelle RL; Woodworth JR
Diabetes; 1994 Mar; 43(3):396-402. PubMed ID: 8314011
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM.
Torlone E; Fanelli C; Rambotti AM; Kassi G; Modarelli F; Di Vincenzo A; Epifano L; Ciofetta M; Pampanelli S; Brunetti P
Diabetologia; 1994 Jul; 37(7):713-20. PubMed ID: 7958544
[TBL] [Abstract][Full Text] [Related]
3. Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control.
Trautmann ME
Horm Metab Res; 1994 Dec; 26(12):588-90. PubMed ID: 7705764
[TBL] [Abstract][Full Text] [Related]
4. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue.
DeFelippis MR; Bakaysa DL; Bell MA; Heady MA; Li S; Pye S; Youngman KM; Radziuk J; Frank BH
J Pharm Sci; 1998 Feb; 87(2):170-6. PubMed ID: 9519149
[TBL] [Abstract][Full Text] [Related]
6. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
[TBL] [Abstract][Full Text] [Related]
7. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia.
Howey DC; Bowsher RR; Brunelle RL; Rowe HM; Santa PF; Downing-Shelton J; Woodworth JR
Clin Pharmacol Ther; 1995 Oct; 58(4):459-69. PubMed ID: 7586939
[TBL] [Abstract][Full Text] [Related]
8. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
[TBL] [Abstract][Full Text] [Related]
9. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM.
Torlone E; Pampanelli S; Lalli C; Del Sindaco P; Di Vincenzo A; Rambotti AM; Modarelli F; Epifano L; Kassi G; Perriello G; Brunetti P; Bolli G
Diabetes Care; 1996 Sep; 19(9):945-52. PubMed ID: 8875087
[TBL] [Abstract][Full Text] [Related]
10. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
[TBL] [Abstract][Full Text] [Related]
11. Preparation of a microcrystalline suspension formulation of Lys(B28)Pro(B29)-human insulin with ultralente properties.
Richards JP; Stickelmeyer MP; Frank BH; Pye S; Barbeau M; Radziuk J; Smith GD; DeFelippis MR
J Pharm Sci; 1999 Sep; 88(9):861-7. PubMed ID: 10479347
[TBL] [Abstract][Full Text] [Related]
12. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
Jacobs MA; Salobir B; Popp-Snijders C; Ader H; Heine RJ
Diabet Med; 1997 Mar; 14(3):248-57. PubMed ID: 9088775
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin.
Heinemann L; Chantelau EA; Starke AA
Diabete Metab; 1992; 18(1):21-4. PubMed ID: 1563532
[TBL] [Abstract][Full Text] [Related]
14. Assembly and dissociation of human insulin and LysB28ProB29-insulin hexamers: a comparison study.
Birnbaum DT; Kilcomons MA; DeFelippis MR; Beals JM
Pharm Res; 1997 Jan; 14(1):25-36. PubMed ID: 9034217
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of [Lys(B28), Pro(B29)]-human insulin in patients with diabetes mellitus.
Akalin S; Erbas T; Yilmaz MT; Ilkova H; Satman I; Ersanli Z; Karsidag K; Damci T; Bagriacik N
Isr J Med Sci; 1997 Nov; 33(11):716-9. PubMed ID: 9434806
[TBL] [Abstract][Full Text] [Related]
16. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
17. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
Attia N; Jones TW; Holcombe J; Tamborlane WV
Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures.
Woodworth JR; Howey DC; Bowsher RR; Brunelle RL; Rowe HM; Compton J; Cerimele B
Diabetes Care; 1994 May; 17(5):366-71. PubMed ID: 8062601
[TBL] [Abstract][Full Text] [Related]
19. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
20. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
Heinemann L; Klappoth W; Rave K; Hompesch B; Linkeschowa R; Heise T
Diabetes Care; 2000 Sep; 23(9):1343-7. PubMed ID: 10977030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
